- Home
- SNAL vs MAIA Comparison
SNAL vs MAIA Comparison
Compare SNAL & MAIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNAL
- MAIA
- Stock Information
- Founded
- SNAL 2000
- MAIA 2018
- Country
- SNAL United States
- MAIA United States
- Employees
- SNAL N/A
- MAIA N/A
- Industry
- SNAL Computer Software: Prepackaged Software
- MAIA Biotechnology: Pharmaceutical Preparations
- Sector
- SNAL Technology
- MAIA Health Care
- Exchange
- SNAL Nasdaq
- MAIA Nasdaq
- Market Cap
- SNAL 45.1M
- MAIA 44.9M
- IPO Year
- SNAL 2022
- MAIA 2022
- Fundamental
- Price
- SNAL $1.11
- MAIA $1.30
- Analyst Decision
- SNAL
- MAIA
- Analyst Count
- SNAL 0
- MAIA 0
- Target Price
- SNAL N/A
- MAIA N/A
- AVG Volume (30 Days)
- SNAL 97.1K
- MAIA 1.0M
- Earning Date
- SNAL 11-13-2025
- MAIA 11-07-2025
- Dividend Yield
- SNAL N/A
- MAIA N/A
- EPS Growth
- SNAL N/A
- MAIA N/A
- EPS
- SNAL N/A
- MAIA N/A
- Revenue
- SNAL $91,041,290.00
- MAIA N/A
- Revenue This Year
- SNAL $13.87
- MAIA N/A
- Revenue Next Year
- SNAL $26.20
- MAIA N/A
- P/E Ratio
- SNAL N/A
- MAIA N/A
- Revenue Growth
- SNAL 24.25
- MAIA N/A
- 52 Week Low
- SNAL $0.64
- MAIA $1.26
- 52 Week High
- SNAL $3.42
- MAIA $3.48
- Technical
- Relative Strength Index (RSI)
- SNAL 52.74
- MAIA 38.74
- Support Level
- SNAL $0.96
- MAIA $1.26
- Resistance Level
- SNAL $1.20
- MAIA $1.57
- Average True Range (ATR)
- SNAL 0.08
- MAIA 0.11
- MACD
- SNAL 0.00
- MAIA -0.01
- Stochastic Oscillator
- SNAL 62.50
- MAIA 8.70
About SNAL Snail Inc.
Snail Inc is an independent developer and publisher of interactive digital entertainment for consumers around the world, with a portfolio of premium games designed for use on a variety of platforms, including consoles, PC's, and mobile devices. The geographic presence of the company is in the United States and the International market, where the majority of its revenue comes from the United States.
About MAIA MAIA Biotechnology Inc.
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. THIO (6-thio-dG or 6-thio-2 '-deoxyguanosine), its lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. Patients with advanced NSCLC will be treated first with THIO followed a few days later by the immune checkpoint inhibitor Libtayo (cemiplimab), manufactured and commercialized by Regeneron.